Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just bought 4 My Pillows because I can't -uckin sleep. lol. 273 fixes that problem. Wake up people.
Right. It's a $45.00 per share chart. Market is sleeping or biased against. imo. Woo. Ya. Crooked market.
Talon 38. What drug out their currently beats 273 in the Alzheimer's space?TIA
Get ready for $4 and $5 gasoline again on the west coast. AVXL cheap at $25.00 per share with todays trial result's. Looking at $55.00. That's cheap.
She has been studying CNS disease for 40 years. She saw what A2-73 did in the RETT trial and she liked the results. A2-73 is a break through drug. imo
Woops didn't see was already posted. Short interest down 16% from last. Wa
I hope your feeling better. :)
Negotiations can take time. Allows folks to buy more walnuts over the weekend.
Right. That is if we don't get bought out for $75 share over the weekend. Would be cheap for the best CNS biotech company in it's space. imo.
5 plus years of proven safety and drug trials better than the current standard of care. Approved.
We will make American people healthy again. Thank you Anavex.
Crowd roars with thanks. :)
Chinese are interest in AVXL. imo
Great post, Nidan. Thanks.
So what happens if an interested company offers 10 Billion or lets say 15 billion for AVXL just for number reference? 1. Would the share holders know about it? 2. Would stock price market cap go to reflected offer price? Thanks
Well yeah. The brokerage houses are giving us a price target of $12 and $17 per share. That is just with the current company update.
Right on, Nidan. Makes sense. My biggest fear is to be out of the stock waking up one morning at a $25.00 open. GLTU and Happy New Year.
JWC3 - Makes total sense. At what point does the price start to reflect real company value?
This current share price should be all of $30.00 right now with current updated company information. imo.
Current market cap is way undervalued. Market cap should be around 1.5 billion with current drug trial results and supporting professional documentation on A2-73 alone.Not to mention the rest of the company drug pipeline. All imo.
Remember - No brain bleed happening here.
RICO Marketers. imo
Treden2 - Yes. Missling said he is discussing accelerated approval with the FDA. Early in the CC. Transcripts should show this.
Discussing accelerated approval with FDA on Rett syndrome trial results.
He's the happiest miserable person I ever seen. lol.
With positive trial results in Rett and PDD now it stands to reason that results in Alzheimer's will be good as well. imo
tred2 - Updated chart is awesome. Thanks!
JWC3 - My guess is also Autism. We'll see.
Boom. A2-73 worth 10 Billion.imo.
In November 2020, Anavex presented data at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) 2020 Conference, reporting top-line results from the proof-of-concept Phase 2 placebo-controlled trial with primary objectives of safety, tolerability, and efficacy in cognition of ANAVEX®2-73 in patients in Parkinson’s disease dementia (PDD) compared to placebo. Both primary objectives of the study were met. The results show clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX®2-73 supporting progression to further development in upcoming Phase 2/3 studies
https://finance.yahoo.com/news/anavex-life-sciences-reports-fiscal-120000990.html
Also ZERO DEBT, Bourbon. That's a big deal.
2014 - More walnuts dude.
Right. FDA ready to approve BIIB brain bleed aducanub. lol. No safety problems here. lol.
Why even talk about conditional approval? Common Man. The drug beat primary and secondary end points in the Rett drug trial. Five plus years of proven safety. No other drug beats A2-73 in CNS disease. APPROVED. That's it. No more dancing around. This drug is worth $10 billion right now. imo
Thursday, December 17, 2020
Biogen Agrees To Pay $22 Million To Resolve Alleged False Claims Act Liability For Paying Kickbacks
Pharmaceutical company Biogen, Inc. (Biogen), based in Cambridge, Massachusetts, has agreed to pay $22 million to resolve claims that it violated the False Claims Act by illegally using foundations as a conduit to pay the copays of Medicare patients taking Biogen’s multiple sclerosis drugs, Avonex and Tysabri, the Justice Department announced today.
When a Medicare beneficiary obtains a prescription drug covered by Medicare, the beneficiary may be required to make a partial payment, which may take the form of a copayment, coinsurance, or a deductible (collectively “copays”). Congress included copay requirements in the Medicare program, in part, to serve as a check on health care costs, including the prices that pharmaceutical manufacturers can demand for their drugs.
“The resolution announced today, like prior settlements concerning similar misconduct, demonstrates the government’s commitment to hold accountable companies that pay kickbacks to undermine important constraints on rising drug costs,” said Acting Assistant Attorney Jeffrey Bossert Clark of the Department of Justice’s Civil Division. “Drug companies that illegally manipulate charitable patient assistance programs to subsidize copays for their own products will be held accountable.”
“Biogen coordinated with ACS to game the foundation system by timing its payments to two foundations with its transfer of financially needy free drug patients, all so that Biogen could obtain significant financial rewards,” said First Assistant United States Attorney Nathaniel R. Mendell. “By treating the foundations simply as conduits to pay the co-pays of its own patients, Biogen violated the anti-kickback statute and undermined Medicare’s co-pay structure, which Congress intended as a safeguard against inflated drug prices. We commend ACS for resolving this matter expeditiously and Biogen for resolving this matter on a cooperative basis.”
“Kickback schemes can undermine our healthcare system and lead to higher costs for the Medicare program,” said Phillip Coyne, Special Agent in Charge, Office of the Inspector General of the Department of Health and Human Service’s Boston Regional Office. “We will continue to hold pharmaceutical companies and specialty pharmacies accountable if they work together to subvert the charitable donation process and violate the prohibition on the payment of kickbacks.”
Under the Anti-Kickback Statute, a pharmaceutical company is prohibited from offering or paying, directly or indirectly, any remuneration—which includes money or any other thing of value— to induce Medicare patients to purchase the company’s drugs. This prohibition extends to the payment of patients’ copay obligations.
Biogen sells Avonex and Tysabri, which are approved for treatment of multiple sclerosis. The government alleged that Biogen engaged in a prohibited kickback scheme by using two foundations, which claim 501(c)(3) status for tax purposes, as conduits to pay the copay obligations of Medicare patients to induce those patients to purchase Medicare-reimbursed Avonex and Tysabri prescriptions. As part of the scheme, Biogen identified for its vendor, Advanced Care Scripts (ACS), certain patients in Biogen’s Avonex or Tysabri free drug program. Biogen then worked with ACS to transfer these patients to the foundations, which received contemporaneous payments from Biogen and then covered the costs of Medicare copays for most or all of these patients. Medicare paid the remaining portion of the patients’ Avonex or Tysabri claims. The government alleged that Biogen engaged in this conduct in the first quarter of 2011 for certain Avonex patients, and in the second and third quarters of 2012 and 2013 for certain Tysabri patients.
Biogen et. al., Case No. 17-CV-10192-MLW (D. Mass.).
https://www.justice.gov/opa/pr/biogen-agrees-pay-22-million-resolve-alleged-false-claims-act-liability-paying-kickbacks
Right. Short interest down 9.5%. Rett drug trial report meeting primary and secondary end points are just the beginning of 2-73 efficacy. Have to be crazy to be short this stock. MC is way low for successful CNS biotech drug. We all know that. imo . Happy Holidays T
2014 - The current color of the charts work well for me. You maybe a little outdated. Don't hit the walnuts to hard. Happy Holiday's.
Tempe - Good explanation for me and I'm grateful for it. Thanks for this and Happy Holliday's.
I like Xena's charts she posts. They are a big help in trading.
For whatever reason our market cap in not fairly valued. Missling is a good CEO. Very smart individual that has accomplished a lot with very little expenditures. I believe our current MC should be around 1.5 to 2 billion right now. imo.
Agree. High Frequency Manipulation HFM. Same thing. imo
Right. You have a cutting edge company in technology that has the best safety record ( Over Five years) in a drug that has proven meeting primary and secondary end points in a drug trials in a highly unmet needed area of CNS disease. Many people are dying do to this disease and other CNS diseases.
And what do we wait for? Someone behind a curtain in a 30 year old approval culture to approve this drug. No. I don't think so.